Target
KAT6B
1 abstract
Abstract
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.Org: Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Cancer Center Hospital East, Kashiwa, Japan, Cedars-Sinai Cancer Institute,